ALI Initiative

Acute Lung Injury (ALI) and its more severe form, Acute Respiratory Distress Syndrome (ARDS), represent a spectrum of life-threatening inflammatory lung conditions.

Phase I
Systems Architecture
Systems Architecture
Status: Completed
The Systems Architecture of ALI is published as a web based tool open to public.
Phase II
Publications
Publications
Status: In Progress
A peer-reviewed paper from the ALI Initiative will be published. This phase is in progress
Phase III
In Silico Modeling
In Silico Modeling
Status: Open
In this phase, in silico modeling will develop mathematical models of ALI pathogenesis.
Phase IV
Combination Screening
Combination Screening
Status: Open
Combination Screening will be conducted to identify compounds targeting biological processes in ALI pathogenesis.
Phase V
Patents
Patents
Status: Open
In this phase, a US patent will be filed for the newly discovered combination(s).
Phase VI
Licensing and Manufacturing
Licensing and Manufacturing
Status: Open
The ALI Initiative will license and manufacture nutraceuticals to support treatment of ALI.

Background on ALI

Acute Lung Injury (ALI) and its more severe form, Acute Respiratory Distress Syndrome (ARDS), represent a spectrum of life-threatening inflammatory lung conditions. Characterized by a sudden onset of widespread inflammation in the lungs, ALI/ARDS disrupts the normal gas exchange process, leading to hypoxemia – a dangerously low level of oxygen in the blood. This acute respiratory failure necessitates prompt recognition and intensive care.  ALI/ARDS isn't a primary disease but rather a complex pulmonary response to various direct or indirect insults. Common triggers include severe infections like pneumonia and sepsis, trauma, aspiration of gastric contents, and other systemic inflammatory conditions. The hallmark of ALI/ARDS is an increase in permeability of the alveolar-capillary barrier, causing protein-rich fluid to leak into the alveoli, impairing surfactant function and leading to alveolar collapse. Understanding the intricate pathophysiology of ALI/ARDS is crucial for developing effective diagnostic and therapeutic strategies aimed at improving patient outcomes.

Systems Architecture

The Systems Architecture of ALI is published as a web based tool open to public . Click below to interact with the Systems Architecture

Publication

A peer-reviewed paper from the ALI Initiative will be published for the benefit of community. This phase is in progress

In Silico Modeling

In this phase, the ALI initiative will conduct in silico modeling to identify and test the efficacy of natural compounds against the cytokine storm, apoptosis and oxidative stress.

Combination Screening

In this phase, combination screening will be performed to identify potential ingredient/compounds that target the biological process implicated in ALI pathogenesis. This phase is yet to begin

Patents

The Open Science Institute® through its ALI Initiative is moving towards getting patents for a revolutionary molecule that effectively combats ALI disease, contributing breakthrough real solutions to society worldwide.

Licensing and Manufacturing

The ALI Initiative plans to discover, develop, license and manufacture proprietary nutraceuticals to support treatment of ALI. Support our mission to bring this innovation to those who need it most. Please support this phase by donating to the ALI Initiative

Health-product-label-09-10-2025